Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Androgen Effect on Klinefelter Syndrome Motor Outcome
This study is currently recruiting participants.
Verified by National Institute of Neurological Disorders and Stroke (NINDS), December 2008
Sponsors and Collaborators: Thomas Jefferson University
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT00348946
  Purpose

The purpose of this study is to evaluate the effects of low-dose androgen on the motor and cognitive development of boys with Klinefelter syndrome.


Condition Intervention Phase
Klinefelter Syndrome
Drug: androgen oxandrolone
Other: placebo
Phase II

Genetics Home Reference related topics: Klinefelter syndrome
MedlinePlus related topics: Klinefelter's Syndrome
Drug Information available for: Oxandrolone
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety Study
Official Title: Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Primary Outcome Measures:
  • Evaluation of several aspects of motor function including muscle strength, motor response speed, simple repetitive movement, and complex nonrepetitive motor action, previously shown to be impaired in boys with Klinefelter syndrome. [ Time Frame: 2 years per subject ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 150
Study Start Date: July 2006
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator Drug: androgen oxandrolone
Oxandrolone or placebo capsule, .06 >mg/kg/day, orally, for 2 years
2: Placebo Comparator Other: placebo
an inactive substance

Detailed Description:

Klinefelter syndrome (KS), a genetic disorder that affects males only, is characterized by having an extra X chromosome. The phenotype — or physical and learning features — includes testicular failure, tall stature, and specific cognitive and behavioral attributes such as diminished motor function, language-based learning difficulties, poor self-image, and shyness. The KS phenotype may be the result of androgen deficiency in utero, infancy, and childhood. For individuals with KS, androgen replacement is standard treatment in adolescence and adulthood but has not been used earlier in childhood or included in the standard medical care of KS children ages 4 to 12.

The purpose of this study is to examine the effects of androgen on learning and development in boys with KS. Researchers also want to determine if low-dose androgen replacement at an early age will improve some of the learning difficulties associated with the disorder. The overall goal of this study is to address questions regarding the relationship of early androgen deficiency to learning and motor function.

Participants in the study will be randomized to one of two treatment groups, receiving either oxandrolone (low-dose androgen) or placebo, for two years. All participants will be evaluated for safety at the beginning of the study and at 3, 6, 12, 18, and 24 months. Also at the beginning of the study and every 3 to 6 months thereafter (for a total of 6 visits), the researchers will perform a careful history and physical examination and a bone age X-ray, and obtain a blood sample.

Participation in the trial will last two years and includes 6 clinic visits.

  Eligibility

Ages Eligible for Study:   4 Years to 12 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Karyotype diagnosis of Klinefelter syndrome
  • Chronological age of 4-12 years
  • No treatment with androgen in the past year

Exclusion Criteria:

  • Major liver, kidney or other systemic disease
  • Variant karyotypes including 47,XYY males
  • Evidence of spontaneous onset of puberty, defined as testicular size > 4ml
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00348946

Contacts
Contact: Judith Ross, MD 215-955-1648 Judith.Ross@mail.tju.edu

Locations
United States, Pennsylvania
Thomas Jefferson University, Department of Pediatrics, 1025 Walnut Street, Suite 726 Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Judith L. Ross, M.D.     215-955-1648        
Principal Investigator: Judith L. Ross, M.D.            
Sponsors and Collaborators
Thomas Jefferson University
Investigators
Principal Investigator: Judith L. Ross, M.D. Thomas Jefferson University
Investigator: Martha Zeger, M.D. Thomas Jefferson University, Co-Investigator
  More Information

Responsible Party: Thomas Jefferson University ( Judith L. Ross, MD, Principal Investigator, Professor, Department of Pediatrics )
Study ID Numbers: R01NS050597-01A2
Study First Received: July 3, 2006
Last Updated: December 4, 2008
ClinicalTrials.gov Identifier: NCT00348946  
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
Klinefelter syndrome
androgen
androgen oxandrolone

Study placed in the following topic categories:
Chromosomal abnormalities
Gonadal Disorders
Klinefelter Syndrome
Chromosome Disorders
Endocrine System Diseases
Sex Differentiation Disorders
Oxandrolone
Urogenital Abnormalities
Hypogonadism
Genetic Diseases, Inborn
Klinefelter syndrome
Endocrinopathy
Congenital Abnormalities

Additional relevant MeSH terms:
Anabolic Agents
Pathologic Processes
Disease
Syndrome
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Sex Chromosome Disorders
Hormones
Pharmacologic Actions
Androgens

ClinicalTrials.gov processed this record on January 14, 2009